Business
Mallinckrodt Names Dr. Marek J. Honczarenko as EVP and Chief Scientific Officer
Mallinckrodt plc today announced the appointment of Dr. Marek J. Honczarenko as Executive Vice President and Chief Scientific Officer, effective September 29, 2025. Dr. Honczarenko, currently the SVP and Head of Development at Sun Pharmaceutical Industries ("Sun Pharma"), will succeed Dr. Peter Richardson, who, as previously announced, has decided to leave the Company to pursue other interests.
About this update from Sun Pharmaceutical Industries Limited
[{"type":"text","content":"DUBLIN, Sept. 22, 2025 /PRNewswire/ -- Mallinckrodt plc today announced the appointment of Dr. Marek J. Honczarenko as Executive Vice President and Chief Scientific Officer, effective September 29, 2025. Dr. Honczarenko, currently the SVP and Head of Development at Sun Pharmaceutical Industries ("Sun Pharma"), will succeed Dr. Peter Richardson, who, as previously announced, has decided to leave the Company to pursue other interests.","length":446,"tagName":"p"},{"type":"image","alt":"Mallinckrodt plc Appoints Dr. Marek J. Honczarenko as Executive Vice President and Chief Scientific Officer","displaySize":"","headline":null,"caption":"Mallinckrodt plc Appoints Dr. Marek J. Honczarenko as Executive Vice President and Chief Scientific Officer","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":351,"url":"https://media.zenfs.com/en/prnewswire.com/643272be50dde2146c20b6567e1f02ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o4ocL6ZxOI997PnCR_Ef3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYxOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/643272be50dde2146c20b6567e1f02ef","width":400,"height":351}},"href":"https://mma.prnewswire.com/media/2778071/Mallinckrodt_plc_Dr_Marek.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"At Sun Pharma, Dr. Honczarenko has responsibility for driving strategy and execution of the company's innovative medicines pipeline across all therapeutic areas and regions, including setting the strategic direction for the research and development organization and advancing the company's pipeline of specialty investigational medicines. Dr. Honczarenko's record of success includes delivering approvals for several transformational immunology medicines, including AbbVie's Skyrizi and Rinvoq, GlaxoSmithKline's Benlysta, Nucala, and Jesduvroq, Bristol Myers Squibb's Orencia, and recently Sun Pharma's Leqselvi.","length":641,"tagName":"p"},{"type":"text","content":""We are excited to have Marek join Mallinckrodt at a time when we are poised to advance our own pipeline of specialty therapeutics," said Siggi Olafsson, Mallinckrodt's President and Chief Executive Officer. "With the completion in July of our merger with Endo and our plan this year to establish a branded business upon the spin-off of our generi...